IL15 and hematologic disorder: For example, two ongoing phase I clinical trials are treating hematologic malignancies with CAR NK cells and membrane-bound IL-15 (mbIL-15), which has been shown to increase NK cell proliferation and cytotoxic function in preclinical studies in an autocrine fashion (NCT04623944, NCT05020678) (101).